Neuilly sur Seine, France

Alain Le Ridant

USPTO Granted Patents = 4 


Average Co-Inventor Count = 4.8

ph-index = 2

Forward Citations = 34(Granted Patents)


Company Filing History:


Years Active: 1988-2008

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Alain Le Ridant

Introduction

Alain Le Ridant is a notable inventor based in Neuilly sur Seine, France. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds with potential therapeutic applications. With a total of 4 patents to his name, Le Ridant's work has garnered attention in the pharmaceutical industry.

Latest Patents

One of his latest patents includes the invention of 3-(4-oxo-4H-chromen-2-yl)-(1H)-quinolin-4-one derivatives. This patent details a method for preparing these compounds and pharmaceutical compositions containing them. The medicinal products derived from this invention are particularly useful as anti-cancer agents. Another notable patent involves N-benzylpiperazine compounds, which further showcases his innovative approach to drug development.

Career Highlights

Throughout his career, Alain Le Ridant has worked with prominent companies in the pharmaceutical sector. He has been associated with Les Laboratoires Servier, a well-known French pharmaceutical company, and Adir & Cie, where he contributed to various research and development projects. His expertise in medicinal chemistry has played a crucial role in advancing the therapeutic potential of new compounds.

Collaborations

Le Ridant has collaborated with several professionals in his field, including Catherine Harpey and Frederic Bonte. These collaborations have enriched his research and contributed to the successful development of his patented inventions.

Conclusion

Alain Le Ridant's innovative work in medicinal chemistry has led to the development of valuable pharmaceutical compounds. His contributions continue to impact the field, particularly in the search for effective anti-cancer agents.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…